tiprankstipranks
Trending News
More News >
UG Healthcare Corp. Ltd. (SG:8K7)
SGX:8K7
Singapore Market
Advertisement

UG Healthcare Corp. Ltd. (8K7) AI Stock Analysis

Compare
0 Followers

Top Page

SG:8K7

UG Healthcare Corp. Ltd.

(SGX:8K7)

Rating:47Neutral
Price Target:
S$0.00
▼(-100.00% Downside)
UG Healthcare Corp. Ltd. faces significant challenges with profitability and cash flow, impacting its financial performance score. Technical analysis suggests neutral to bearish momentum, while valuation metrics highlight profitability concerns. These factors collectively result in a below-average stock score.
Positive Factors
Revenue Growth
Strong revenue growth indicates a robust recovery and expanding market presence, enhancing long-term business sustainability.
Integrated Supply Chain
An integrated supply chain enhances operational efficiency and cost management, providing a competitive advantage in the PPE market.
Strategic Partnerships
Strategic partnerships expand market reach and sales volume, supporting sustained revenue growth and market penetration.
Negative Factors
Profitability Challenges
Ongoing profitability issues can hinder reinvestment and growth, impacting long-term financial health and shareholder value.
Cash Flow Issues
Negative cash flow limits the company's ability to fund operations and invest in growth, posing risks to financial stability.
Negative Return on Equity
A negative return on equity indicates inefficient use of shareholder funds, potentially deterring investment and growth opportunities.

UG Healthcare Corp. Ltd. (8K7) vs. iShares MSCI Singapore ETF (EWS)

UG Healthcare Corp. Ltd. Business Overview & Revenue Model

Company DescriptionUG Healthcare Corporation Limited, an investment holding company, manufactures and sells disposable gloves. It operates through three segments: Latex Examination Gloves, Nitrile Examination Gloves, and Other Ancillary Products. The company offers latex examination gloves that comprise single chlorinated and double chlorinated polymer coated gloves, as well as nitrile examination gloves. It also distributes ancillary products, including surgical gloves, vinyl and cleanroom disposable gloves, face masks, and other medical disposables, as well as shoe covers and other related products; and provides business and management consultancy services. The company's products are used in healthcare, food and beverage, industrial, high technology manufacturing, automotive, research and development, and beauty sectors. It serves customers under the Unigloves brand name in Malaysia, Europe, North America, South America, Africa, and rest of Asia. The company was founded in 1989 and is based in Singapore.
How the Company Makes MoneyUG Healthcare Corp. Ltd. generates revenue primarily through the sale of its glove products. The company's revenue streams are largely divided between manufacturing and distribution. In the manufacturing segment, UG Healthcare produces a variety of gloves, including latex, nitrile, and vinyl, which are then sold in bulk to distributors and end-users in the healthcare, industrial, and food sectors. The distribution segment involves the company's own established distribution network, which allows direct access to various markets globally. Additionally, the company benefits from strategic partnerships and collaborations with regional distributors and healthcare providers, which enhance its market reach and sales volume. UG Healthcare's revenue is significantly influenced by global demand for PPE, particularly during health crises such as the COVID-19 pandemic, which saw a surge in demand for medical gloves.

UG Healthcare Corp. Ltd. Financial Statement Overview

Summary
UG Healthcare Corp. Ltd. is facing financial headwinds with declining revenues and negative profitability metrics, suggesting operational inefficiencies or market challenges. While the balance sheet shows solid equity, increasing leverage is a concern. Cash flow struggles highlight the need for strategic operational improvements to enhance liquidity and profitability.
Income Statement
45
Neutral
The company has faced a decline in revenue over recent years, dropping significantly from 2021 to 2023. Despite an increase in revenue from 2023 to 2024, profitability remains a challenge with negative EBIT and net income margins. The gross profit margin has improved but remains insufficient to offset operational losses, indicating potential inefficiencies or cost management issues.
Balance Sheet
60
Neutral
The balance sheet shows a relatively strong equity base with a healthy equity ratio. However, the debt-to-equity ratio has increased, indicating rising financial leverage. Despite this, the company maintains a strong cash position, which provides some buffer against financial risks.
Cash Flow
40
Negative
The company is experiencing negative operating and free cash flows, reflecting operational challenges and potential cash management issues. This is concerning as negative cash flows persist, despite a minor improvement in free cash flow from 2023 to 2024.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue94.93M144.07M115.20M101.13M232.60M338.40M
Gross Profit3.43M34.74M25.87M1.45M84.39M196.16M
EBITDA-20.11M2.47M-3.86M-24.53M53.37M159.46M
Net Income-20.93M-3.79M-6.06M-20.73M36.80M118.77M
Balance Sheet
Total Assets215.39M232.35M226.45M230.00M288.04M268.29M
Cash, Cash Equivalents and Short-Term Investments45.13M23.29M28.00M61.74M100.22M68.44M
Total Debt28.46M47.36M43.72M31.13M17.98M16.74M
Total Liabilities44.08M76.03M65.17M48.81M52.98M73.53M
Stockholders Equity171.94M158.73M163.39M180.84M228.90M190.64M
Cash Flow
Free Cash Flow-36.98M-8.11M-20.71M-47.17M31.63M61.47M
Operating Cash Flow-34.35M-4.78M-18.16M-39.14M53.95M81.16M
Investing Cash Flow-2.63M-3.21M-22.73M-8.03M-21.19M-18.89M
Financing Cash Flow4.62M3.24M8.36M8.70M-973.00K-3.14M

UG Healthcare Corp. Ltd. Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.10
Price Trends
50DMA
0.11
Negative
100DMA
0.11
Negative
200DMA
0.11
Negative
Market Momentum
MACD
>-0.01
Positive
RSI
45.31
Neutral
STOCH
52.94
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SG:8K7, the sentiment is Negative. The current price of 0.1 is below the 20-day moving average (MA) of 0.10, below the 50-day MA of 0.11, and below the 200-day MA of 0.11, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 45.31 is Neutral, neither overbought nor oversold. The STOCH value of 52.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SG:8K7.

UG Healthcare Corp. Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
67
Neutral
S$1.15B15.5616.42%9.26%18.55%-5.89%
51
Neutral
$8.02B-0.39-43.38%2.20%22.34%-2.13%
47
Neutral
S$64.25M-2.36%25.06%37.11%
S$106.67M16.519.86%
S$68.30M-15.97%
S$14.42M7.5119.16%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SG:8K7
UG Healthcare Corp. Ltd.
0.10
-0.02
-16.67%
SG:AP4
Riverstone Holdings
0.78
-0.02
-2.50%
SG:1J5
Hyphens Pharma International Ltd.
0.35
0.07
25.00%
SG:546
Medtecs International Corporation Ltd.
0.13
-0.01
-7.14%
SG:BFK
Pharmesis International Ltd.
0.46
0.34
283.33%

UG Healthcare Corp. Ltd. Corporate Events

UG Healthcare Announces Board Changes Following Executive Director’s Retirement
Jun 24, 2025

UG Healthcare Corporation Limited has announced changes to its Board of Directors, effective June 25, 2025, due to the retirement of Executive Director Mr. Lee Keck Keong. The company will continue to be led by Joint CEOs, Mr. Lee Jun Yih and Mr. Lee Jun Linn, who will oversee the group’s operations and strategic direction. The Board has expressed gratitude for Mr. Lee’s contributions. The new Board composition includes Wong Fook Choy Sunny as Non-Executive Chairman and Independent Director, along with other directors.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 06, 2025